Clinical Trial Update: Trial of Ipilimumab After Isolated Limb Perfusion, in Patients With Metastases Melanoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated ipilimumab after isolated limb perfusion in patients with in-transit metastatic melanoma (Stage IIIB-IIIC); the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• ipilimumab (ipilimumab)

Snippet

Sponsor: Gustave Roussy, Cancer Campus, Grand Paris | Conditions: In-transit Metastases Melanoma Stage IIIB and IIIC | Phase 2 | Status: COMPLETED